Media headlines about TG Therapeutics (NASDAQ:TGTX) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TG Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.4390479422125 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Zacks: Analysts Expect TG Therapeutics, Inc (TGTX) Will Announce Quarterly Sales of $40,000.00 (americanbankingnews.com)
- Notable Friday Option Activity: MUR, AA, TGTX (nasdaq.com)
- TG Therapeutics: Assessing The Investment Prospects Of A Potential Big Winner (seekingalpha.com)
- Zacks: Brokerages Expect TG Therapeutics, Inc (TGTX) to Post -$0.55 EPS (americanbankingnews.com)
- TG Therapeutics (TGTX) Announces Upcoming Data Presentations at ASCO and EHA (streetinsider.com)
A number of research firms have weighed in on TGTX. B. Riley reissued a “buy” rating and issued a $27.00 price objective (up from $21.50) on shares of TG Therapeutics in a research report on Friday, March 9th. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 6th. Raymond James reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Thursday, April 19th. ValuEngine raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. TG Therapeutics presently has an average rating of “Buy” and an average price target of $24.60.
Shares of TG Therapeutics opened at $13.90 on Tuesday, MarketBeat reports. TG Therapeutics has a one year low of $7.25 and a one year high of $17.35. The stock has a market cap of $1.06 billion, a PE ratio of -7.28 and a beta of 1.21.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.15). TG Therapeutics had a negative return on equity of 170.83% and a negative net margin of 87,025.00%. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. research analysts forecast that TG Therapeutics will post -1.99 EPS for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.